Zydus Lifesciences Ltd

Mid Cap

Healthcare Sector

reflects a positive outlook for the share price

reflects a neutral outlook for the share price

reflects a negative outlook for the share price

The analysts information is for reference only and does not\n  represents an investment recommendation.

Analyst recommendation reflect the views of analysts who follow and write research reports.

Company Information is an introduction to the company’s business that details what it sell, how it was founded, what their mission is, how they manufacture or source their products, and why they serve customers.

Zydus Lifesciences launched Anyra™, India's first biosimilar of Aflibercept, and received USFDA approval for bosentan tablets, enhancing its offerings in ophthalmic care and pulmonary hypertension.

Zydus Gains USFDA Approval and Launches New Products - 19 Feb, 2026

Zydus Lifesciences has received final USFDA approval for Bosentan 32 mg tablets, aimed at treating pulmonary arterial hypertension in children, with annual sales of $9.3 million.

Zydus Lifesciences Secures FDA Approval for Bosentan - 18 Feb, 2026

Zydus Lifesciences launched PEPAIR, an affordable OPEP device for respiratory issues. The company is also transitioning to an innovation-driven model, achieving strong growth.

Zydus Lifesciences Launches Innovative Device and Reports Growth - 17 Feb, 2026

Zydus Lifesciences has received final USFDA approval for Ammonium Lactate Cream, 12%, which is expected to generate annual sales of $15 million.

Zydus Lifesciences Secures FDA Approval for Cream - 14 Feb, 2026

Zydus Lifesciences has settled a patent dispute with Astellas Pharma over Myrbetriq, agreeing to pay $120 million and allowing continued marketing of its generic version in the US.

Zydus Settles Patent Dispute with Astellas Pharma - 12 Feb, 2026

Zydus Lifesciences received Supreme Court approval to launch its cancer drug biosimilar, overcoming legal challenges from Bristol Myers Squibb. The company also plans significant product launches and growth strategies for FY27.

Zydus Lifesciences Gains Approval for Cancer Drug Biosimilar - 11 Feb, 2026

Zydus Lifesciences' Q3FY26 results show a 1.8% increase in net profit to Rs 1,042 crore and a 30% rise in revenue to Rs 6,864 crore, driven by strong performance in pharmaceuticals and consumer wellness.

Zydus Lifesciences Reports Strong Q3FY26 Results - 09 Feb, 2026

Zydus Lifesciences announced that the USFDA granted Orphan Drug Designation to Desidustat for Sickle Cell Disease, providing eligibility for development incentives and potential marketing exclusivity.

Zydus Gains Orphan Drug Status for Desidustat - 06 Feb, 2026

Zydus Lifesciences has obtained tentative approval from the USFDA for Dapagliflozin Tablets, a generic diabetes medication, with annual US sales reaching approximately $10.49 billion.

Zydus Lifesciences Secures FDA Approval for Diabetes Drug - 04 Feb, 2026

Zydus Lifesciences announced that the US FDA concluded its inspection of the Ankleshwar facility, issuing three observations but no data integrity concerns. The company plans to address these observations promptly.

Zydus Lifesciences Faces FDA Observations at Facility - 27 Jan, 2026

Zydus Lifesciences has launched Tishtha, the world's first biosimilar of nivolumab, in India at a fraction of the original drug's price, aiming to improve access for over 500,000 cancer patients.

Zydus Launches Affordable Nivolumab Biosimilar in India - 22 Jan, 2026

Zydus Lifesciences is considering acquiring a majority stake in US-based Ardelyx Inc. for $2.2–2.5 billion, supported by a Rs 5,000 crore equity raise. The company reported strong Q2 FY26 results, with a 17% revenue increase and a 38% rise in net profit.

Zydus Lifesciences Plans Major Acquisition in US - 21 Jan, 2026

Price to Earnings Ratio or Price to Earnings Multiple is the ratio of the share price of a stock to its earnings per share (EPS). It provides an indication of whether a stock at its current market price is expensive or cheap.

The price/earnings-to-growth ratio, or the PEG ratio, is a metric that helps investors value a stock by taking into account a company's market price, its earnings, and its future growth prospects.

Enterprise value (EV) is the total value of a company, defined in terms of its financing. It includes both the current share price (market capitalization) and the cost to pay off debt (net debt, or debt minus cash).

Alpha measures the amount that the investment has returned in comparison to the market index or other broad benchmark that it is compared against.

Beta measures a stock's volatility, the degree to which its price fluctuates in relation to the overall stock market. In other words, it gives a sense of the stock's risk compared to that of the greater market.

Dividend yield measures the quantum of earnings by way of total dividends that investors make by investing in that company.

The debt-to-total-assets ratio shows how much of a business is owned by creditors (people it has borrowed money from) compared with how much of the company's assets are owned by shareholders.

Operating cash flow (OCF) is a measure of the amount of cash generated by a company's normal business operations. Operating cash flow indicates whether a company can generate sufficient positive cash flow to maintain and grow its operations.

This widget shows the information about the stock's peers in consideration along with the different data for those peers so that the user can compare the stock with the other similar stock and invest accordingly.

Promoter holding is the amount of share of the company that is owned by the promoters. The promoters are the company's founders, who hold a majority stake in the company's capital.

A foreign institutional investor (FII) is an investor or investment fund investing in a country outside of the one in which it is registered or headquartered.

A mutual fund is a pool of money managed by a professional Fund Manager. It is a trust that collects money from a number of investors who share a common investment objective and invests the same in equities, bonds, money market instruments, and other securities.

Retail investors execute their trades through traditional or online brokerage firms or other types of investment accounts. Retail investors purchase securities for their own personal accounts and often trade in dramatically smaller amounts as compared to institutional investors.

This widget shows the bifurcation of stocks based on the percentage of stake with the different types of shareholders.

This widget will help value the stock based on the Price to Earning ratio of the stock and compare the valuation with the industry value and other similar stocks. It even shows the timeline of the valuation of the stock and its highest and lowest valuation over time.
A Time Series data is provided which compares the historical stock PE with Industry PE over the period of 5 years.

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

Revenue is up for the last 2 quarters, 6.23K Cr → 6.97K Cr (in ₹), with an average increase of 10.7% per quarter

This section gives you an insight into how the revenue of the company has moved for the last few quarters.

Revenue Rich

Promoters have increased holdings from 74.99% to 75.00% in Dec 2025 quarter

This section gives you an insight into how the Promoter Holding has changed for the stock over the last few quarters.

Promoter Holding Up

Retail Investor have increased holdings from 6.80% to 6.85% in Dec 2025 quarter

This section gives you an insight into how the Retail Investors Holding has changed for the stock over last few quarters.

Retail Holding Up

In the last 1 month, ZYDUSLIFE stock has moved up by 3.3%

This section gives you an insight into the price movement of the stock for the last few quarters.

Price Rise

Mutual Funds have increased holdings from 4.70% to 4.71% in Dec 2025 quarter

This section gives you an insight into how the Mutual Funds Holding has changed for the stock over last few quarters.

MF Holding Up

In the last 1 year, Torrent Pharmaceuticals Ltd has given 34.9% return, outperforming this stock by 32.8%

This section gives you an insight into how the peers have performed as compared to this company in the last 1 year.

Against Peers

In the last 3 years, Torrent Pharmaceuticals Ltd has given 184.2% return, outperforming this stock by 88.2%

This section gives you an insight into how the peers have performed as compared to this company in the last 3 years.

Netprofit is down for the last 3 quarters, 1.46K Cr → 1.04K Cr (in ₹), with an average decrease of 15.7% per quarter

This section gives you an insight into how the profit for the company has been for the last few quarters.

Profit Down

Foreign Institutions have decreased holdings from 7.34% to 7.06% in Dec 2025 quarter

This section gives you an insight into how the FII Holding has changed for the stock over last few quarters.

FII Holding Down

BSE Healthcare

S&P BSE 250 LargeMidCap

NIFTY PHARMA

S&P BSE Dividend Stability

S&P BSE 400 MidSmallCap

Nifty 200

Nifty100 Eq Weig

NIFTY 100

Nifty Healthcare

Nifty Next 50

BSE 200

Nifty100 Quality

S&P BSE 150 MidCap

Nifty LargeMidcap 250

BSE 500

Nifty 500

Parag Parikh Flexi Cap Direct Growth

Kotak Flexicap Fund Direct Growth

ICICI Prudential Large Cap Fund Direct Plan Growth

ICICI Prudential India Opportunities Fund Direct Growth

ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund Direct Growth

Zydus Lifesciences receives USFDA approval for bosentan tablets for pulmonary arterial hypertension, expanding its product portfolio.

Zydus Lifesciences Ltd’s net profit jumped 1.82% since last year same period to ₹1,042.10Cr in the Q3 2025-2026. On a quarterly growth basis, Zydus Lifesciences Ltd has generated -17.2% fall in its net profits since last 3-months.

Zydus Lifesciences Ltd Earnings Results

In the quarter ending March 2025, Zydus Lifesciences Ltd has declared dividend of ₹11.00 per share on 19 May 2025 - translating a dividend yield of 1.21%.

Name	Value	Action
MACD level (12,26)	-1.04	Bullish
CCI (20)	360.01	Bearish
RSI (14)	37.57	Neutral
Momentum (10)	-1.95	Bearish
ADI (14)	34.25	Bearish
Ultimate Oscillator (7,14,28)	7.71	Bearish

Name	Value	Action
SMA (20)	901.71	Bearish
EMA (20)	901.79	Bearish
VWMA (20)	901.29	Bearish
SMA (50)	904.06	Bearish
EMA (50)	903.57	Bearish
SMA (200)	907.52	Bearish
EMA (200)	906.96	Bearish
KAMA (200)	903.74	Bearish
DEMA (200)	904.66	Bearish

Zydus Lifesciences Ltd (ZYDUSLIFE)

Summary

Overall

Oscillators

Moving Averages